Jul 1, 2026 04:05PM

Jun 16, 2026 04:00PM

Apr 16, 2026 04:05PM

Mar 2, 2026 06:01AM

Mar 2, 2026 02:00AM

Jan 5, 2026 07:03AM

Jan 5, 2026 07:00AM Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

Dec 8, 2025 02:54AM

Dec 6, 2025 09:30AM

Oct 13, 2025 05:04AM

Oct 10, 2025 11:27AM

Jun 1, 2025 08:00AM

Mar 3, 2025 06:46AM

Mar 3, 2025 06:45AM Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Jan 6, 2025 04:05PM

Nov 22, 2024 05:21AM

Jan 31, 2024 04:09PM

Jan 31, 2024 04:05PM

Oct 30, 2023 04:08PM

Oct 30, 2023 04:05PM

Nov 16, 2022 04:05PM Protagonist Therapeutics Reports Granting of Inducement Award

Apr 19, 2022 04:15PM

Oct 11, 2021 09:21AM

Sep 15, 2021 05:05PM

Mar 23, 2021 09:28AM

Mar 22, 2021 05:44PM

Dec 16, 2020 09:23AM

May 24, 2018 04:30PM Protagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer

Mar 26, 2018 09:13AM

May 30, 2017 09:32AM

1,165,265 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All